| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
DOCK2
DOCK2 (dedicator of cytokinesis 2), a guanine nucleotide exchange factor (GEF) specifically expressed in hematopoietic cells that activates Rac1 and Rac2 in lymphocytes. DOCK2-IN-1 binds reversibly to the DOCK2 DHR-2 domain with an IC50 of 0.51 uM (selective) and 19.1 uM in some assays, inhibiting its GEF activity and blocking Rac activation in lymphocytes. |
|---|---|
| ln Vitro |
In vitro, DOCK2-IN-1 binds reversibly to the DOCK2 DHR-2 domain to inhibit its catalytic activity. It blocks both chemokine receptor- and antigen receptor-mediated activation of Rac in lymphocytes, with dramatic inhibition of chemotactic responses and T-cell activation. At 19.1 uM, it serves as a DOCK2 inhibitor, suppressing lymphocyte migration and cytoskeleton reorganization.
|
| ln Vivo |
DOCK2-IN-1 is a selective DOCK2 inhibitor used primarily for in vitro studies. In in vivo models, DOCK2 inhibition would be expected to suppress lymphocyte migration and T-cell activation, potentially reducing autoimmune disease severity and transplant rejection. However, detailed published in vivo studies for DOCK2-IN-1 are limited; it is primarily an immunology research tool.
|
| Enzyme Assay |
A biochemical GEF activity assay is used to assess DOCK2 inhibition. Purified recombinant DOCK2 DHR-2 domain is incubated with a fluorescently labeled Rac1 substrate and GTPgammaS in the presence of serially diluted DOCK2-IN-1 (0.1-100 uM). GEF activity is measured by fluorescence polarization or by detecting activated Rac (Rac-GTP) using a pull-down assay with the Rac-binding domain of PAK. The IC50 is calculated.
|
| Cell Assay |
For in vitro lymphocyte activation assays, primary mouse or human T cells are isolated from splenocytes or peripheral blood. T cells are pre-incubated with serially diluted DOCK2-IN-1 (0.1-100 uM) for 30 minutes, then stimulated with anti-CD3/anti-CD28 antibodies (for antigen receptor activation) or with chemokines (e.g., SDF-1alpha for CXCR4 activation). Rac activation is measured by Rac-GTP pull-down assay. Chemotaxis is assessed using transwell chambers. T-cell proliferation is measured by CFSE dilution by flow cytometry after 72 hours of stimulation.
|
| Animal Protocol |
No published in vivo animal studies are available for DOCK2-IN-1. For research use, a mouse model of experimental autoimmune encephalomyelitis (EAE, a model of multiple sclerosis) or allogeneic skin transplantation can be used to assess DOCK2 inhibition in vivo. DOCK2-IN-1 is administered intraperitoneally at doses of 10-50 mg/kg daily or every other day. Clinical scores (EAE) or graft survival time (transplant) are monitored. Lymph nodes and spleens are harvested for analysis of T-cell activation and migration.
|
| ADME/Pharmacokinetics |
DOCK2-IN-1 has a molecular weight of 309.32 g/mol and a formula of C12H9BrN4O2. It is a CPYPP analogue. Detailed in vivo PK parameters (e.g., half-life, Cmax, oral bioavailability) are not publicly available. As a small molecule, it is expected to have moderate permeability and may be administered intraperitoneally for in vivo studies. Solubility in DMSO is high.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for DOCK2-IN-1 are not publicly available. As a selective inhibitor of DOCK2, a GEF expressed primarily in hematopoietic cells, potential toxicities may include immunosuppression (increased susceptibility to infections) and impaired lymphocyte development. No significant acute toxicity has been reported at concentrations used in cell-based assays (≤100 uM). Long-term safety studies have not been conducted.
|
| References | |
| Additional Infomation |
DOCK2-IN-1 is a research-grade compound not approved for clinical use. It is used to study the role of DOCK2-mediated Rac activation in lymphocyte chemotaxis, T-cell activation, and immune responses. It has applications in immunology research, autoimmune disease models, and transplant rejection studies. This product is for laboratory research purposes only, not for human therapeutic use.
|
| Molecular Formula |
C16H11CLN2O2
|
|---|---|
| Molecular Weight |
298.723742723465
|
| Exact Mass |
298.05
|
| CAS # |
4590-86-7
|
| PubChem CID |
5750959
|
| Appearance |
Light brown to brown solid powder
|
| LogP |
3.4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
21
|
| Complexity |
457
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1(C2=CC=CC=C2)C(=O)C(=CC2=CC=CC=C2Cl)C(=O)N1
|
| InChi Key |
VEBASGXAFMQOLL-JLHYYAGUSA-N
|
| InChi Code |
InChI=1S/C16H11ClN2O2/c17-14-9-5-4-6-11(14)10-13-15(20)18-19(16(13)21)12-7-2-1-3-8-12/h1-10H,(H,18,20)/b13-10+
|
| Chemical Name |
(4E)-4-[(2-chlorophenyl)methylidene]-1-phenylpyrazolidine-3,5-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 125 mg/mL (418.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3476 mL | 16.7381 mL | 33.4762 mL | |
| 5 mM | 0.6695 mL | 3.3476 mL | 6.6952 mL | |
| 10 mM | 0.3348 mL | 1.6738 mL | 3.3476 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
